Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 361 to 366 of 366 entries
Sorted by: Best Match Show Resources per page
Reply to Wei Liu, Katherine Zukotynski, and Glenn Bauman's Letter to the Editor re: Rachel M. Glicksman, Ur Metser, Douglass Vines, et al. Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis. Eur Urol 2021;80:374-82.

European urology

Glicksman RM, Berlin A.
PMID: 34158186
Eur Urol. 2021 Sep;80(3):e79-e80. doi: 10.1016/j.eururo.2021.06.004. Epub 2021 Jun 20.

No abstract available.

Cite
Glicksman RM, Berlin A. Reply to Wei Liu, Katherine Zukotynski, and Glenn Bauman's Letter to the Editor re: Rachel M. Glicksman, Ur Metser, Douglass Vines, et al. Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis. Eur Urol 2021;80:374-82. Eur Urol. 2021;80(3):e79-e80doi: 10.1016/j.eururo.2021.06.004.
Glicksman, R. M., & Berlin, A. (2021). Reply to Wei Liu, Katherine Zukotynski, and Glenn Bauman's Letter to the Editor re: Rachel M. Glicksman, Ur Metser, Douglass Vines, et al. Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis. Eur Urol 2021;80:374-82. European urology, 80(3), e79-e80. https://doi.org/10.1016/j.eururo.2021.06.004
Glicksman, Rachel M, and Berlin, Alejandro. "Reply to Wei Liu, Katherine Zukotynski, and Glenn Bauman's Letter to the Editor re: Rachel M. Glicksman, Ur Metser, Douglass Vines, et al. Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis. Eur Urol 2021;80:374-82." European urology vol. 80,3 (2021): e79-e80. doi: https://doi.org/10.1016/j.eururo.2021.06.004
Glicksman RM, Berlin A. Reply to Wei Liu, Katherine Zukotynski, and Glenn Bauman's Letter to the Editor re: Rachel M. Glicksman, Ur Metser, Douglass Vines, et al. Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis. Eur Urol 2021;80:374-82. Eur Urol. 2021 Sep;80(3):e79-e80. doi: 10.1016/j.eururo.2021.06.004. Epub 2021 Jun 20. PMID: 34158186.
Copy Download .nbib Format: NLM
On Finding a Better Way.

Respiratory care

Berlin T.
PMID: 33632789
Respir Care. 2021 Mar;66(3):531-532. doi: 10.4187/respcare.08891.

No abstract available.

Cite
Berlin T. On Finding a Better Way. Respir Care. 2021;66(3):531-532doi: 10.4187/respcare.08891.
Berlin, T. (2021). On Finding a Better Way. Respiratory care, 66(3), 531-532. https://doi.org/10.4187/respcare.08891
Berlin, Thomas. "On Finding a Better Way." Respiratory care vol. 66,3 (2021): 531-532. doi: https://doi.org/10.4187/respcare.08891
Berlin T. On Finding a Better Way. Respir Care. 2021 Mar;66(3):531-532. doi: 10.4187/respcare.08891. PMID: 33632789.
Copy Download .nbib Format: NLM
Practical considerations for prostate hypofractionation in the developing world.

Nature reviews. Urology

Yan M, Gouveia AG, Cury FL, Moideen N, Bratti VF, Patrocinio H, Berlin A, Mendez LC, Moraes FY.
PMID: 34389825
Nat Rev Urol. 2021 Nov;18(11):669-685. doi: 10.1038/s41585-021-00498-6. Epub 2021 Aug 13.

External beam radiotherapy is an effective curative treatment option for localized prostate cancer, the most common cancer in men worldwide. However, conventionally fractionated courses of curative external beam radiotherapy are usually 8-9 weeks long, resulting in a substantial burden...

Cite
Yan M, Gouveia AG, Cury FL, et al. Practical considerations for prostate hypofractionation in the developing world. Nat Rev Urol. 2021;18(11):669-685doi: 10.1038/s41585-021-00498-6.
Yan, M., Gouveia, A. G., Cury, F. L., Moideen, N., Bratti, V. F., Patrocinio, H., Berlin, A., Mendez, L. C., & Moraes, F. Y. (2021). Practical considerations for prostate hypofractionation in the developing world. Nature reviews. Urology, 18(11), 669-685. https://doi.org/10.1038/s41585-021-00498-6
Yan, Michael, et al. "Practical considerations for prostate hypofractionation in the developing world." Nature reviews. Urology vol. 18,11 (2021): 669-685. doi: https://doi.org/10.1038/s41585-021-00498-6
Yan M, Gouveia AG, Cury FL, Moideen N, Bratti VF, Patrocinio H, Berlin A, Mendez LC, Moraes FY. Practical considerations for prostate hypofractionation in the developing world. Nat Rev Urol. 2021 Nov;18(11):669-685. doi: 10.1038/s41585-021-00498-6. Epub 2021 Aug 13. PMID: 34389825; PMCID: PMC8361822.
Copy Download .nbib Format: NLM
Redefining Palliative Surgery: The Congenital Cardiac Surgery Experience.

The Annals of thoracic surgery

Blitzer D, Berlin A, Guariento A, Mayer JE.
PMID: 34126074
Ann Thorac Surg. 2022 Feb;113(2):383-385. doi: 10.1016/j.athoracsur.2021.05.052. Epub 2021 Jun 11.

No abstract available.

Cite
Blitzer D, Berlin A, Guariento A, et al. Redefining Palliative Surgery: The Congenital Cardiac Surgery Experience. Ann Thorac Surg. 2021;113(2):383-385doi: 10.1016/j.athoracsur.2021.05.052.
Blitzer, D., Berlin, A., Guariento, A., & Mayer, J. E. (2022). Redefining Palliative Surgery: The Congenital Cardiac Surgery Experience. The Annals of thoracic surgery, 113(2), 383-385. https://doi.org/10.1016/j.athoracsur.2021.05.052
Blitzer, David, et al. "Redefining Palliative Surgery: The Congenital Cardiac Surgery Experience." The Annals of thoracic surgery vol. 113,2 (2022): 383-385. doi: https://doi.org/10.1016/j.athoracsur.2021.05.052
Blitzer D, Berlin A, Guariento A, Mayer JE. Redefining Palliative Surgery: The Congenital Cardiac Surgery Experience. Ann Thorac Surg. 2022 Feb;113(2):383-385. doi: 10.1016/j.athoracsur.2021.05.052. Epub 2021 Jun 11. PMID: 34126074.
Copy Download .nbib Format: NLM
Development and Validation of the Readiness for End-of-Life Conversations (REOLC) Scale.

Frontiers in psychology

Berlin P, Leppin N, Nagelschmidt K, Seifart C, Rief W, von Blanckenburg P.
PMID: 33868137
Front Psychol. 2021 Mar 19;12:662654. doi: 10.3389/fpsyg.2021.662654. eCollection 2021.

No abstract available.

Cite
Berlin P, Leppin N, Nagelschmidt K, et al. Development and Validation of the Readiness for End-of-Life Conversations (REOLC) Scale. Front Psychol. 2021;12:662654doi: 10.3389/fpsyg.2021.662654.
Berlin, P., Leppin, N., Nagelschmidt, K., Seifart, C., Rief, W., & von Blanckenburg, P. (2021). Development and Validation of the Readiness for End-of-Life Conversations (REOLC) Scale. Frontiers in psychology, 12662654. https://doi.org/10.3389/fpsyg.2021.662654
Berlin, Pia, et al. "Development and Validation of the Readiness for End-of-Life Conversations (REOLC) Scale." Frontiers in psychology vol. 12 (2021): 662654. doi: https://doi.org/10.3389/fpsyg.2021.662654
Berlin P, Leppin N, Nagelschmidt K, Seifart C, Rief W, von Blanckenburg P. Development and Validation of the Readiness for End-of-Life Conversations (REOLC) Scale. Front Psychol. 2021 Mar 19;12:662654. doi: 10.3389/fpsyg.2021.662654. eCollection 2021. PMID: 33868137; PMCID: PMC8044973.
Copy Download .nbib Format: NLM
An Expert Review on the Combination of Relugolix with Definitive Radiation Therapy for Prostate Cancer.

International journal of radiation oncology, biology, physics

Roy S, Zaorsky NG, Bagshaw HP, Berlin A, Koontz B, Nguyen P, Chen R, Dess RT, Jackson WC, Kishan AU, Stish B, Nagar H, Posadas E, Tran PT, Solanki A, Shore ND, Guo G, Ponsky L, Shoag JE, Morgans AK, Garcia JA, Showalter TN, Feng FY, Spratt DE.
PMID: 34923058
Int J Radiat Oncol Biol Phys. 2021 Dec 16; doi: 10.1016/j.ijrobp.2021.12.005. Epub 2021 Dec 16.

Androgen deprivation therapy (ADT) is an integral component in the management of prostate cancer across multiple disease states. Traditionally, luteinizing hormone-releasing hormone (LHRH) agonists constituted the backbone of ADT. However, gonadotropin-releasing hormone receptor hormone (GnRH) antagonists are also available,...

Cite
Roy S, Zaorsky NG, Bagshaw HP, et al. An Expert Review on the Combination of Relugolix with Definitive Radiation Therapy for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2021;doi: 10.1016/j.ijrobp.2021.12.005.
Roy, S., Zaorsky, N. G., Bagshaw, H. P., Berlin, A., Koontz, B., Nguyen, P., Chen, R., Dess, R. T., Jackson, W. C., Kishan, A. U., Stish, B., Nagar, H., Posadas, E., Tran, P. T., Solanki, A., Shore, N. D., Guo, G., Ponsky, L., Shoag, J. E., Morgans, A. K., Garcia, J. A., Showalter, T. N., Feng, F. Y., & Spratt, D. E. (2021). An Expert Review on the Combination of Relugolix with Definitive Radiation Therapy for Prostate Cancer. International journal of radiation oncology, biology, physics, . https://doi.org/10.1016/j.ijrobp.2021.12.005
Roy, Soumyajit, et al. "An Expert Review on the Combination of Relugolix with Definitive Radiation Therapy for Prostate Cancer." International journal of radiation oncology, biology, physics vol. (2021). doi: https://doi.org/10.1016/j.ijrobp.2021.12.005
Roy S, Zaorsky NG, Bagshaw HP, Berlin A, Koontz B, Nguyen P, Chen R, Dess RT, Jackson WC, Kishan AU, Stish B, Nagar H, Posadas E, Tran PT, Solanki A, Shore ND, Guo G, Ponsky L, Shoag JE, Morgans AK, Garcia JA, Showalter TN, Feng FY, Spratt DE. An Expert Review on the Combination of Relugolix with Definitive Radiation Therapy for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2021 Dec 16; doi: 10.1016/j.ijrobp.2021.12.005. Epub 2021 Dec 16. PMID: 34923058.
Copy Download .nbib Format: NLM
Showing 361 to 366 of 366 entries